Condition

Cholangiocarcinoma clinical trials and research

• 78Clinical trials
• 26NIH research projects
• 1New in 30 days
• 24Countries

Newest Cholangiocarcinoma clinical trials

All recruiting trials (78)

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Breath test to help detect gastrointestinal cancers early

  A breath test that looks for signals in exhaled air to see if someone with gut cancer symptoms might have oesophageal, stomach, pancreatic, liver, or colorectal cancer and need urgent testing.

  Recruiting Imperial College London · Maidstone, Kent and 5 other locations · NCT07714538

• Can an imaging tracer help predict if cholangiocarcinoma patients will respond to standard therapy

  This study tests whether an imaging tracer called [18F]FTT used with PET/CT can predict how newly diagnosed cholangiocarcinoma patients will respond to the standard treatment of gemcitabine, cisplatin, and durvalumab.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07673341

• Dual-target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

  This trial tests a ready-to-use CAR-NK cell therapy that targets HER2 and CEACAM5 in adults with unresectable or metastatic biliary tract cancers after standard therapy to see if it can help control the disease.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07641036

• KRAS G12V cancer patients get TCR1188-ABC cell therapy

  This early-phase trial tests whether TCR1188-ABC cells can safely be given to adults with KRAS G12V-mutated metastatic cancers to see if it can help some types of pancreatic, biliary, colorectal, or lung cancer.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07594067

• Suprapapillary Metal Stent vs. Routine Drainage for Malignant Hilar Biliary Obstruction

  This trial tests whether placing a self-expanding metal stent above the papilla works better than the standard transpapillary drainage for patients with cancer-caused bile duct blockage near the liver.

  Recruiting Hospital de Clinicas de Porto Alegre · Porto Alegre, Rio Grande do Sul and 1 other locations · NCT07558304

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

• Olutasidenib drug interaction testing for IDH1‑mutant cancers

  This trial tests whether the cancer drug olutasidenib changes how the body processes other medicines in adults with IDH1‑mutation positive cancers.

  Recruiting at 2 sites Phase 4 Rigel Pharmaceuticals · Orange, California and 1 other locations · NCT07486713

• 68Ga‑FAPI‑46 PET/CT to improve initial staging for pancreatic and bile duct cancer

  This will try 68Ga‑FAPI‑46 PET/CT scans in people newly diagnosed with pancreatic or bile duct cancer to see if they find hidden spread that CT or MRI miss.

  Recruiting Phase 2 University Hospital, Bordeaux · Pessac · NCT07478523

• Laryngopharyngeal injuries after breathing tube placement during general anesthesia

  This project sees how often and why people who had a breathing tube during general anesthesia developed hoarseness or other throat problems after non-ear–nose–throat surgery.

  Recruiting Zhejiang University · Hangzhou, Zhejiang and 1 other locations · NCT07359586

• PULSAR with dual immunotherapy and chemotherapy for cholangiocarcinoma

  This trial will test whether adding PULSAR radiotherapy to two immunotherapy drugs plus gemcitabine and cisplatin helps people with locally advanced or metastatic cholangiocarcinoma.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07291947

• Gemcitabine and cisplatin plus PD‑1/PD‑L1 immunotherapy for advanced cholangiocarcinoma

  It will try combining standard gemcitabine-plus-cisplatin chemotherapy with a PD‑1/PD‑L1 immunotherapy for adults with advanced, unresectable or metastatic cholangiocarcinoma.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07291063

• Spirulina to protect the liver and help recovery after partial hepatectomy

  This trial will test whether taking spirulina tablets before and after surgery helps people with cholangiocarcinoma protect their liver and recover faster after a partial hepatectomy.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07263217

• Ivosidenib as maintenance after adjuvant chemotherapy for curative IDH1‑mutant intrahepatic cholangiocarcinoma

  This trial tests whether taking ivosidenib after standard adjuvant chemotherapy can reduce recurrence in adults with completely removed (R0) IDH1‑mutant intrahepatic cholangiocarcinoma.

  Recruiting at 15 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Aachen and 14 other locations · NCT07260175

• Noninvasive blood miRNA test to screen for multiple gastrointestinal cancers.

  This project will test whether a blood-based microRNA panel can detect several types of gastrointestinal cancer in adults using stored blood samples.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07224750

• LY4337713 for people with FAP-positive ovarian, breast, pancreatic, colorectal, or esophageal cancers

  This trial tests LY4337713, a FAP-targeted lutetium-177 therapy, in people with advanced cancers that show high levels of fibroblast activation protein (FAP).

  Recruiting at 17 sites Phase 1 Eli Lilly and Company · Newport Beach, California and 29 other locations · NCT07213791

• In-depth characterisation of biliary strictures and hepato‑pancreato‑biliary focal lesions to support new diagnostic technologies

  This project will collect detailed imaging and tissue data from adults with suspected bile duct, liver, pancreatic, or gallbladder lesions to help develop and test better diagnostic tools.

  Recruiting University of Nottingham · Nottingham · NCT07206355

• Preoperative Lymph Node Assessment in Cholangiocarcinoma using Endoscopic Ultrasound

  This study tests how well preoperative endoscopic ultrasound (EUS) finds lymph node metastases in adults with presumed resectable or certain unresectable cholangiocarcinomas to see if surgery should proceed.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland and 5 other locations · NCT07161869

• Tissue adhesive (Glubran®2) to reinforce pancreaticojejunostomy in soft pancreas

  This trial will test whether adding a tissue adhesive glue (Glubran®2) to the pancreatic-jejunal connection reduces postoperative pancreatic leaks in adults with a soft pancreas undergoing pancreaticoduodenectomy.

  Recruiting Minia University · Minya, Minya Governorate · NCT07155525

• Testing GV20-0251 for advanced or treatment‑resistant solid tumors

  This study will test whether GV20-0251 is safe and tolerable when given every three weeks to adults with advanced or treatment‑resistant solid tumors such as liver, lung, pancreatic cancer, and melanoma.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07106827

• Sacituzumab tirumotecan plus pucotenlimab for advanced cholangiocarcinoma

  This trial will test whether combining sacituzumab tirumotecan with pucotenlimab can help people with unresectable or metastatic cholangiocarcinoma.

  Recruiting Phase 2 Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT07105852

• Streamlined radioembolization for cholangiocarcinoma and metastatic liver cancer

  This study tests whether skipping the pre-procedure nuclear lung scan is safe and speeds up treatment for adults with small (≤7 cm), limited-number metastatic liver tumors or intrahepatic cholangiocarcinoma.

  Recruiting Seoul National University Hospital · Goyang-si and 3 other locations · NCT07043387

• Neoadjuvant tislelizumab with SBRT and gemcitabine/platinum chemotherapy for borderline or unresectable hilar bile duct cancer

  This trial will see if precise radiotherapy (SBRT) followed by the PD‑1 drug tislelizumab plus gemcitabine and platinum chemotherapy can shrink tumors enough to allow surgery and improve survival in people with borderline resectable or unresectable hilar cholangiocarcinoma.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07030140

• Anti-blood-vessel therapy after immunotherapy for advanced bile duct or gallbladder cancer.

  This study will test whether giving the anti-angiogenic drug anlotinib after first-line immunotherapy helps people with advanced bile duct or gallbladder cancer live longer without their disease getting worse.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07025174

• Using bile analysis to diagnose unclear narrowings of the bile ducts

  This project will test whether analyzing bile with molecular 'omics' together with routine biliary brushings or biopsies can help find cancer in people with indeterminate biliary strictures.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China · NCT07007832

• Skin tests to check biotherapy allergies in cancer patients

  We are testing skin tests to see if cancer patients treated with biotherapies have allergies or hypersensitivity to those drugs.

  Recruiting University Hospital, Angers · Angers · NCT06971848

• Combining portal and hepatic vein embolization for liver cancer treatment

  This study is testing if combining two types of vein treatments can help more people with liver cancer have surgery and live longer.

  Recruiting Maastricht University · New Haven, Connecticut and 54 other locations · NCT06914648

• Collecting blood and tissue samples from patients with primary liver cancer

  This study is collecting blood and tissue samples from patients with primary liver cancer to help researchers find new treatments for the disease.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Pavia · NCT06899854

• Assessing blood biomarkers and MRI for liver cancer patients undergoing radiation therapy

  This study is testing if using special MRI scans and blood tests can help doctors keep track of liver health in patients with liver cancer who are getting radiation therapy.

  Recruiting Montefiore Medical Center · The Bronx, New York · NCT06899152

• Monitoring tumor changes and treatment response in bile duct and liver cancer patients

  This study is testing how different factors affect treatment responses in people with bile duct or liver cancer by looking at their blood and tumor samples during and after their treatment.

  Recruiting at 3 sites Region Skane · Kristianstad and 2 other locations · NCT06877637

• A breath test to detect liver cancer and monitor liver health

  This study is testing a new breath test to see if it can help find liver cancer earlier and keep track of liver health in adults with liver issues or certain stomach symptoms.

  Recruiting Imperial College London · London · NCT06864195

• ImmunoPET imaging for solid tumors targeting Trop2

  This study is testing a new imaging method to see if it can help diagnose solid tumors like bladder and prostate cancer better than current methods.

  Recruiting Phase 2/3 RenJi Hospital · Shanghai · NCT06851663

• Testing PHST001 for advanced solid tumors

  This study is testing a new treatment called PHST001 to see if it is safe and effective for people with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 20 sites Phase 1 Pheast Therapeutics · Beverly Hills, California and 19 other locations · NCT06840886

• Testing MGC028 in patients with advanced solid tumors

  This study is testing a new treatment called MGC028 to see if it is safe and can help adults with advanced solid tumors that can't be removed or have spread.

  Recruiting at 7 sites Phase 1 MacroGenics · San Francisco, California and 6 other locations · NCT06723236

• Combining chemotherapy, immunotherapy, and targeted therapy for advanced cholangiocarcinoma

  This study is testing a new combination of chemotherapy, immunotherapy, and targeted therapy to see if it helps people with advanced cholangiocarcinoma feel better and live longer.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06718257

• Evaluating biomarkers in advanced biliary tract cancer treatment with lenvatinib and pembrolizumab

  This study is testing if a combination of two drugs, lenvatinib and pembrolizumab, can help people with advanced biliary tract cancer and is looking for clues in their genetic data to see how well the treatment works.

  Recruiting CHA University · Seongnam-si, Gyeonggi-do · NCT06648057

• Using ivosidenib for advanced cholangiocarcinoma with IDH1 mutation after previous treatments

  This study is testing how well the drug ivosidenib works for people with advanced bile duct cancer who have already tried other treatments and have a specific gene mutation.

  Recruiting at 19 sites iOMEDICO AG · Augsburg and 18 other locations · NCT06607302

• Combining chemotherapy, immunotherapy, radiation, and heat treatment for advanced biliary tract cancer

  This study is testing a new combination of chemotherapy, immunotherapy, radiation, and heat treatment to see if it can help people with advanced biliary tract cancer who can’t have surgery.

  Recruiting at 2 sites Phase 1 University of Maryland, Baltimore · Baltimore, Maryland and 1 other locations · NCT06546969

• Observational study of rare primary liver cancers in France

  This study looks at rare types of liver cancer in France to see how they behave and how well different treatments work for patients.

  Recruiting at 29 sites Federation Francophone de Cancerologie Digestive · Amiens and 39 other locations · NCT06541652

• Using a new imaging agent to detect various cancers

  This study is testing a new imaging agent to see if it can better detect certain cancers in adults compared to standard imaging methods.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06503146

• Combining Durvalumab and Olaparib for Advanced Cholangiocarcinoma Treatment

  This study is testing if combining two drugs, durvalumab and olaparib, can help people with advanced cholangiocarcinoma feel better and live longer after their initial chemotherapy.

  Recruiting at 7 sites Phase 2 Australasian Gastro-Intestinal Trials Group · Camperdown, New South Wales and 7 other locations · NCT06441747

• Combining cadonilimab with chemotherapy for advanced bile duct cancer

  This study is testing if combining a new drug called cadonilimab with chemotherapy can help people with advanced bile duct cancer who haven't responded to other treatments.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT06438822

• Combined Proton Therapy and Liver Transplant for Hilar Cholangiocarcinoma

  This trial tests whether adding proton beam therapy plus chemotherapy and liver transplantation helps people with hilar cholangiocarcinoma.

  Recruiting at 2 sites The Christie NHS Foundation Trust · London and 1 other locations · NCT06434493

• Bile proteomic test to diagnose cholangiocarcinoma

  We will try a proteomic analysis of bile to see if it can detect cholangiocarcinoma in adults who are having diagnostic bile sampling.

  Recruiting University Hospital, Bordeaux · Pessac · NCT06416397

• Using FAPI PET-CT to Improve Treatment for Proximal Cholangiocarcinoma

  This study is testing if a new type of imaging called FAPI PET-CT can help doctors better plan treatment for patients with bile duct cancer by finding cancer spread more accurately than regular scans.

  Recruiting at 2 sites Phase 2/3 Erasmus Medical Center · Amsterdam and 2 other locations · NCT06355427

• Liquid biopsy to differentiate types of primary liver cancer

  This study is testing a new blood test to see if it can tell the difference between two types of liver cancer, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, to help doctors diagnose patients more safely.

  Recruiting at 5 sites City of Hope Medical Center · Duarte, California and 4 other locations · NCT06342414

• Neoadjuvant chemotherapy and immunotherapy for advanced cholangiocarcinoma

  This study is testing a combination of chemotherapy and immunotherapy before surgery to see if it can help people with advanced cholangiocarcinoma have fewer cancer recurrences within a year after their operation.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples, Italia and 5 other locations · NCT06341764

• Engaging cancer patients in genomic testing decisions

  This study is testing if letting cancer patients choose what genetic information they want to receive helps them feel more informed and satisfied with their health decisions.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT06340646

• Combining Afatinib and Pemigatinib for Advanced Solid Tumors

  This study is testing a combination of two drugs, Afatinib and Pemigatinib, to see if they can safely help people with advanced solid tumors that have specific genetic changes.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT06302621

• Navigating Care for Liver Cancer Patients

  This study is trying to learn about the experiences of liver cancer patients to create a better support program that helps them and their families manage their care.

  Recruiting University of Miami · Miami, Florida · NCT06260943

• Testing MDX2001 for advanced solid tumors

  This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Denver, Colorado and 5 other locations · NCT06239194

• Treatment of Taxane-resistant Cancers with Paclitaxel Polymeric Micelles

  This study is testing a new form of chemotherapy called Paclitaxel Polymeric Micelles to see if it can help people with advanced cancers that didn't respond to standard Taxane treatments.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT06199895

• Endoscopic radiofrequency ablation for unresectable bile duct cancer

  This study tests whether adding intraductal radiofrequency ablation to standard chemotherapy and bile duct stenting helps people with unresectable bile duct cancer.

  Recruiting at 9 sites Universitätsklinikum Hamburg-Eppendorf · Berlin and 8 other locations · NCT06175845

• Treatment using CEA-targeted CAR-T cells for advanced solid tumors

  This study is testing a new type of immune therapy using CAR-T cells to see if it can help people with advanced solid tumors that have a specific marker called CEA.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhu, Anhui · NCT06126406

• Combination chemotherapy for patients with resectable biliary tract cancers

  This study is testing a new combination of chemotherapy drugs before surgery to see if it helps people with certain types of biliary tract cancers live longer without their cancer coming back.

  Recruiting at 2 sites Phase 2/3 Gruppo Oncologico del Nord-Ovest · Ancona and 18 other locations · NCT06037980

• Combining pembrolizumab with chemotherapy for treating intrahepatic cholangiocarcinoma before surgery

  This study is testing if adding pembrolizumab to standard chemotherapy can help people with a type of liver cancer have better outcomes after surgery.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05967182

• Combining GNS561 and Trametinib for Advanced Cholangiocarcinoma with KRAS Mutation

  This study is testing if a new combination of two drugs, GNS561 and trametinib, can help people with advanced bile duct cancer and a specific gene mutation who haven't had success with standard treatments.

  Recruiting at 9 sites Phase 1/2 Genfit · Los Angeles, California and 10 other locations · NCT05874414

• Evaluating liver embolization techniques for tumor management

  This study tests different liver embolization methods to see how well they help people with liver tumors live longer and maintain liver function while they continue their usual treatments.

  Recruiting IRCCS San Raffaele · Milan · NCT05714124

• Combination treatment for advanced bile duct cancer

  This study is testing a new combination treatment for patients with advanced bile duct cancer that can't be surgically removed to see if it helps them feel better and live longer.

  Recruiting Phase 2 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT05655949

• Comparing blood samples from cancer-draining veins to standard veins in patients with liver and pancreatic cancers

  This study is testing if taking blood samples from veins near liver and pancreatic tumors can help find cancer DNA better than using regular veins in patients getting biopsies.

  Recruiting University of California, Irvine · Orange, California · NCT05497531

• Community-based program to prevent liver cancer in Thailand

  This study is testing a community health program in Thailand to see if educating people about liver cancer risks can help them make better choices and prevent the disease.

  Recruiting McMaster University · Phu Wiang, Changwat Khon Kaen · NCT05321992

• Combining PDS01ADC with targeted liver chemotherapy for certain cancers

  This study is testing if a new cancer treatment that combines an immune booster with targeted liver chemotherapy can help people with certain advanced cancers feel better and live longer.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05286814

• Registry for advanced endoscopic procedures in gastrointestinal conditions

  This study is collecting information from patients who are getting special endoscopic procedures for serious gastrointestinal conditions to see how well these treatments work.

  Recruiting Region Stockholm · Stockholm · NCT05187312

• Finding new biomarkers for biliary tract cancer and gallbladder cancer

  This study is trying to find new markers in blood and tissue samples from patients with biliary tract and gallbladder cancer to help doctors diagnose the disease earlier and predict how well treatments will work.

  Recruiting Herlev and Gentofte Hospital · Herlev, Copenhagen · NCT05184400

• Understanding risk factors and genetic changes in biliary tree cancers

  This study is trying to find out what causes biliary tree cancers and how genetic changes can help doctors understand treatment responses in patients with these cancers.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT05179486

• Characterizing liver cancer and chronic liver disease through sample collection

  This study is trying to find early signs of liver cancer by collecting and comparing blood, urine, and liver samples from people with liver cancer and those with chronic liver disease.

  Recruiting University of Oxford · Oxford, Oxfordshire · NCT04946773

• Understanding BAP1 Hereditary Cancer Risks

  This study is trying to find out how common certain cancers are in people with BAP1 gene mutations to help improve screening and treatment for them and their families.

  Recruiting Ohio State University · Columbus, Ohio · NCT04792463

• Collecting bile samples from patients with Primary Sclerosing Cholangitis and controls

  This study is collecting bile samples from people with Primary Sclerosing Cholangitis and healthy individuals to see how the disease affects the body and find new ways to treat it.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT04753996

• Evaluating Tivozanib for Biliary Tract Cancers

  This study is testing if a new drug called tivozanib can help people with advanced bile duct cancer who have already had chemotherapy feel better and improve their health.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04645160

• Targeting rare cancers with genomic therapy

  This study is testing if personalized treatments based on the genetic makeup of rare tumors can help patients feel better and improve their outcomes.

  Recruiting TargetCancer Foundation · Cambridge, Massachusetts · NCT04504604

• BOLD-100 combined with FOLFOX for advanced solid tumors

  This study is testing if a new drug called BOLD-100 can work better with FOLFOX chemotherapy for people with advanced solid tumors like colorectal and pancreatic cancers.

  Recruiting at 26 sites Phase 1/2 Bold Therapeutics, Inc. · Santa Monica, California and 27 other locations · NCT04421820

• Observational cohort of patients with liver cancer

  This study is tracking patients with aggressive liver cancers to see how their treatment and outcomes change over time, hoping to improve their care and find better treatment options.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT04340986

• Comparing two techniques for accessing the bile duct in patients with biliary diseases

  This study is testing two different methods for accessing the bile duct to see which one works better for patients with biliary diseases like cholangiocarcinoma and choledocholithiasis.

  Recruiting Coordinación de Investigación en Salud, Mexico · Mexico City, Mexico City · NCT04037007

• Examining the link between skinfold thickness and survival in certain cancers

  This study tests if measuring skinfold thickness can help predict how long people with pancreatic, cholangiocarcinoma, and gallbladder cancers might live, especially those struggling with weight loss.

  Recruiting Samsung Medical Center · Seoul · NCT03637569

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

• Biobank for cholestatic liver diseases

  This study is collecting samples and health information from people with cholestatic liver diseases to see if it can help us better understand these conditions and improve how we detect and predict them.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT03445585

• Collecting tumor tissue samples from patients undergoing surgery or biopsy for cancer

  This study is collecting tissue samples from cancer patients having surgery or biopsies to see if they can find new ways to treat different types of cancer.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT01915225

NIH-funded research (26)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• A new mouse model to study intrahepatic cholangiocarcinoma and its immunotherapy

  A new mouse model helps researchers understand intrahepatic cholangiocarcinoma and test immune-based treatments to improve outcomes.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11413830

• Radiation plus a patient’s own immune cells to boost cholangiocarcinoma treatment

  This project tests a therapy that combines precise radiation and the patient’s own dendritic cells with immune drugs to help fight intrahepatic cholangiocarcinoma in people who cannot have surgery.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11408644

• Worldwide genetics of bile duct (cholangiocarcinoma)

  Researchers are looking for genetic patterns that raise the risk of bile duct cancer in people from diverse regions worldwide.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11399765

• MKK4 and Liver Regeneration after Major Liver Surgery

  A study at Mayo Clinic will test a new drug, HRX215, to help people regrow liver tissue after major liver surgery for cancer.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11393014

• New mouse model to improve immune therapy for intrahepatic bile duct (cholangiocarcinoma) cancer

  This project builds a new mouse model to help make immune-based treatments work better for people with intrahepatic cholangiocarcinoma, a type of bile duct liver cancer.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11392619

• Mutant IDH in bile duct cancer and its impact on immune response

  A patient-facing look at how mutations in IDH1 drive bile duct cancer and how targeting this mutation could help immune cells fight the tumor.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11392376

• Understanding a tumor-promoting immune pathway in bile duct cancer

  A new NIH grant aims to test how a specific immune protein, B7-H4, helps cholangiocarcinoma grow and how blocking it might slow the cancer.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11384315

• How bile duct cancer (cholangiocarcinoma) develops

  This project looks at whether changes in chronic bile-duct disease and activity of liver receptors called FXR and CAR drive bile duct cancer, aiming to help people with conditions like primary sclerosing cholangitis.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11312650

• Organoid-Immune Cell Models to Test Cholangiocarcinoma Treatments

  Researchers are building patient-derived tumor models that include immune cells to test how cholangiocarcinoma may respond to immune therapies plus chemotherapy.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11296375

• Understanding how tumor variety affects bile duct cancer (iCCA)

  Researchers will study how differences within a single tumor and between primary and metastatic sites influence disease progression and treatment response in intrahepatic cholangiocarcinoma, using human samples and mouse models.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11281627

• Sugar markers for bile duct cancer (cholangiocarcinoma)

  Looking at specific sugar patterns in blood and tissue to help find bile duct cancer earlier in people at risk.

  NIH research Medical University of South Carolina · Charleston, United States · NIH-11241168

• Blocking the protein B7-H4 that helps bile duct cancer grow

  This research looks at whether blocking the protein B7-H4 can slow tumor growth in people with intrahepatic bile duct cancer.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11168772

• How an IDH1 mutation changes bile duct cancer and its response to treatment

  This work looks at how a common IDH1 mutation changes bile duct cancer and whether blocking that mutation can help the immune system fight the tumor.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11143811

• Using radiation and your own immune cells to boost immunotherapy for intrahepatic bile-duct (liver) cancer

  This approach combines focused liver radiation, injections of your own dendritic immune cells, and two immune drugs to try to help people with unresectable intrahepatic bile-duct cancer live longer without the disease getting worse.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11142663

• Understanding how cholangiocarcinoma develops at the molecular level

  This study is looking into how cholangiocarcinoma, a cancer that affects the bile ducts, develops, especially in people with certain liver conditions, to find ways to detect it early and improve treatment options.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11106737

• Noninvasive methods to identify mutations in liver cancer

  This study is looking for better ways to diagnose a type of liver cancer called intrahepatic cholangiocarcinoma (iCCA) by using noninvasive methods to check for important genetic changes, which can help doctors choose the best treatment for patients.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11092682

• Understanding how patient-derived cancer organoids respond to treatment in cholangiocarcinoma

  This study is looking at ways to create mini versions of your cancer to see how different treatments work, with the hope of finding better options for people with bile duct cancer.

  NIH research Wm S. Middleton Memorial Veterans Hosp · Madison, United States · NIH-11063125

• Finding new treatments for bile duct cancer

  This study is looking at bile duct cancer to find specific markers in the genes and proteins that could help create better treatments for patients, making it easier to fight this tough disease.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11053521

• Identifying glycan biomarkers for cholangiocarcinoma

  This study is looking at how certain changes in sugars found in blood and tissue can help doctors spot bile duct cancer earlier and tell it apart from other illnesses, with the hope of improving diagnosis and treatment for patients.

  NIH research Medical University of South Carolina · Charleston, United States · NIH-11049609

• Investigating new treatment pathways for a deadly liver cancer

  This study is looking at a type of liver cancer called intrahepatic cholangiocarcinoma and is testing a new approach to treatment that uses a drug called dasatinib for patients whose tumors have certain genetic changes, hoping to find better options than standard chemotherapy.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11044148

• Combining radiation and immune cells to enhance treatment for liver cancer

  This study is testing a new way to help people with a tough type of liver cancer by using strong radiation along with special immune cells from their own body to boost their immune system and help them live longer without the cancer getting worse.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-10998056

• Investigating a new way to treat bile duct cancer

  This study is looking for better treatments for bile duct cancer by exploring how a protein called B7-H4 helps tumors grow, with the hope of finding new ways to fight this tough disease and improve survival for patients.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-10979882

• How mutant IDH affects bile duct cancer

  This study is looking at how a specific mutation in a gene called IDH1 affects bile duct cancer and helps cancer cells hide from the immune system, with the hope of finding better ways to treat this cancer by combining current therapies with new immune treatments.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-10932410

• A new mouse model to study liver cancer and improve its treatment

  This study is looking at a tough type of liver cancer called intrahepatic cholangiocarcinoma and is testing a new mouse model to learn more about how the immune system interacts with this cancer, hoping to find better treatment options that work alongside current therapies.

  NIH research University of California, San Diego · La Jolla, United States · NIH-10931375

• Improving treatment outcomes for patients with advanced bile duct cancer.

  This study is looking at a new way to treat patients with advanced bile duct cancer by comparing a standard chemotherapy with an added treatment delivered directly to the liver, to see which helps people live longer.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-10897008

• Combining therapies to treat bile duct cancer

  This study is exploring new ways to treat cholangiocarcinoma, a tough bile duct cancer, by testing different combinations of drugs to see if they can work better than standard chemotherapy and help patients get longer-lasting results.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-10821442

Related topics

Quick answers

How many Cholangiocarcinoma clinical trials are recruiting right now?

78, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 24 countries. The most sites are in United States (31 trials), China (18 trials), United Kingdom (7 trials), Germany (6 trials), Italy (6 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 14, Phase 1: 8, Phase 1/2: 7, Phase 2/3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →